Skip to Main Content

  • Image not available. Cerebral ischemia is the key pathophysiologic event triggering secondary neuronal injury following severe traumatic brain injury (TBI). Intracellular accumulation of calcium is postulated to be a central pathophysiologic process in amplifying and perpetuating secondary neuronal injury via inhibition of cellular respiration and enzyme activation.
  • Image not available.Guidelines for the Management of Severe Brain Injury, published by the Brain Trauma Foundation/American Association of Neurological Surgeons, serve as the foundation on which clinical decisions in managing adult neurotrauma patients are based; comparable guidelines for infants, children, and adolescents have also been published.
  • Image not available. Correcting and preventing early hypotension (systolic blood pressure less than 90 mm Hg) and hypoxemia (Pao2 less than 60 mm Hg [8.0 kPa]) are primary goals during the initial resuscitative and intensive care of severe TBI patients.
  • Image not available. The principal monitoring parameter for severe TBI patients within the intensive care environment is intracranial pressure (ICP). Cerebral perfusion pressure is also a critical monitoring parameter and should be maintained between 50 and 70 mm Hg (greater than 40 mm Hg in pediatric patients) through the use of fluids, vasopressors, and/or ICP normalization therapy.
  • Image not available. Nonspecific pharmacologic treatment in the management of intracranial hypertension should include analgesics, sedatives, antipyretics, and paralytics under selected circumstances.
  • Image not available. Specific pharmacologic treatment in the management of intracranial hypertension includes mannitol, furosemide, and high-dose pentobarbital. Neither routine use of corticosteroids nor aggressive hyperventilation (i.e., Paco2 less than 25 mm Hg) should be used in the management of intracranial hypertension.
  • Image not available.Phenytoin (or alternatively carbamazepine) should be used to prevent seizures in TBI patients at high risk for the first 7 days after injury. Use of phenytoin for the prophylaxis of posttraumatic seizures usually should be discontinued after 7 days if no seizures are observed.
  • Image not available. Numerous investigational strategies (e.g., calcium antagonists, glutamate antagonists, antioxidants, free-radical scavengers, and progesterone) targeted at interrupting the pathophysiologic cascade of events occurring following severe TBI have been employed, but no proven therapeutic benefits have been identified.

Upon completion of the chapter, the reader will be able to:

  • 1. Describe the most common causes of severe traumatic brain injury (TBI) and the typical age distribution for patients sustaining such injuries.
  • 2. Differentiate between primary and secondary brain injury.
  • 3. Explain the central role of ischemia in triggering secondary neuronal injury following severe TBI.
  • 4. Compare and contrast the process of cellular necrosis and apotosis along the spectrum of secondary neuronal injury.
  • 5. Discuss the cascade of biochemical events proposed to occur following a severe TBI.
  • 6. Evaluate the neurological state of a severe brain injury patient using the Glasgow Coma Scale (GCS) and factors that may affect the GCS in addition to TBI.
  • 7. Summarize the impact of the Brain Trauma Foundation Guidelines for the Management of Severe Brain Injury on the consistency of care for severe TBI patients.
  • 8. Outline several general short-term treatment goals in the acute management of the TBI patient.
  • 9. Formulate a general treatment plan for a severe TBI patient during ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.